Home › Blood Cancers › New Jersey
Blood Cancers clinical trials in New Jersey
21 studies for Blood Cancers are looking for participants at sites in New Jersey.
Cities in New Jersey
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Cancer Institute of New Jersey ( Site 0025), New Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Englewood Hospital and Medical Center, Englewood
- Hackettstown Medical Center, Hackettstown
- Morristown Medical Center, Morristown
- and 6 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Rutgers University Study of the Genetics of Blood Cancers
- Rutgers University, Piscataway
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 110 · All sexes · Updated Oct 1, 2026 · NCT07714044A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Rutgers Cancer Institute of New Jersey, Piscataway
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07572006Genomic Profiling in Cancer Patients
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingObservational study
All ages · All sexes · Updated Sep 24, 2026 · NCT01775072Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Astera Cancer Care ( Site 2732), East Brunswick
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704), Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Hackensack Meridian Health, Hackensack
- Carol G Simon Cancer Center, Morristown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Englewood Hospital and Medical Center, Englewood
RecruitingObservational study
All ages · All sexes · Updated Sep 17, 2026 · NCT04242095Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Atlantic Health, Morristown
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Rutgers Biomedical and Health Sciences, New Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- John Theurer Cancer Center, Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT06665100Mosaic Trial for Stem Cell Transplant Recipients
- Hackensack Meridian Health, Nutley
Recruiting
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT06960993A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07359859Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Hackensack University Medical Center, Hackensack
- Robert Wood Johnson/Cancer Institute of New Jersey, New Brunswick
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07006506A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
- Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities), Middletown
- Memorial Sloan Kettering Bergen (All protocol activities), Montvale
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT07052916A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hackensack University Medical Center, Hackensack
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.